EVAX
Evaxion Biotech A/S ADR · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website evaxion-biotech.com
- Employees(FY) 63
- ISIN US29970R2040
Performance
-1.33%
1W
-7.92%
1M
-8.15%
3M
-50.4%
6M
-45.75%
YTD
-77.45%
1Y
Profile
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Hørsholm, Denmark.
Technical Analysis of EVAX 2024-05-10
Overview:
In analyzing the technical indicators for EVAX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
...Recent News & Updates
- 2023-08-22 21:19
- 2023-08-22 12:11
Q2 2023 Evaxion Biotech A/S Earnings Call(Yahoo Finance)
- 2023-08-17 23:57
- 2023-07-31 19:00
- 2023-07-30 19:00
- 2023-06-04 23:50
Why Are Evaxion Biotech Shares Trading Higher Today(Yahoo Finance)
- 2023-06-03 05:00
- 2023-05-31 18:53
- 2023-05-30 20:30
- 2023-05-25 05:00
- 2023-05-25 05:00
- 2023-05-15 17:47
Evaxion to host R&D Day on May 25, 2023(Yahoo Finance)
- 2023-04-26 19:00
- 2023-04-17 20:00
- 2023-04-12 21:44
- 2023-03-27 19:46
- 2023-03-22 19:55
- 2023-03-14 04:30
- 2023-02-07 21:47
- 2023-02-07 17:30
- 2023-01-18 19:45
- 2023-01-02 19:14
- 2023-01-02 18:30
- 2022-12-14 18:48
- 2022-12-05 19:18
- 2022-12-05 13:00
- 2022-11-16 22:03
- 2022-11-16 17:59
- 2022-11-13 18:13
- 2022-11-09 15:10
Evaxion CEO comments on strategic focus(Yahoo Finance)